Opexa Therapeutics, Inc. (Nasdaq:OPXA) reported financial results for the year ended December 31, 2010 and provided an update on its progress. December 2010: Completed two successful meetings with the FDA, positioning Opexa to pursue a Phase III clinical study for TovaxinÂ® in relapsing-remitting MS (RR-MS); July 2010: Enlisted the support of worldwide thought leaders in MS, neurology, and immunology for newly reconstituted Scientific Advisory Board; April 2010: Presentation of key immunological data at the 62nd annual American Academy of Neurology (NYSE:AAN) conference supporting Tovaxin mechanism of action.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops patient-specific cellular therapies for the treatment of autoimmune diseases.
Experts warn that the U.S. depends upon China for almost all of its supply of rare earths, and has let its own rare earth production languish despite possessing about 15 % of the world's reserves. A draft of a Chinese rare earths plan for 2009-2015 expresses that China's own industrial requirement could soon cause restrictions or bans on the export of rare earths.
The U.S. Geological Survey (USGS) noted that 91 % of U.S. usage of rare earths originated in China between 2005 and 2008.
Constraints on Chinese exports are creating opportunities for non-Chinese projects.
Read more at: http://crwewallstreet.com/?p=16820